{
  "publication/title": "Not enough information is available.",
  "publication/authors": "Not enough information is available.",
  "publication/journal": "Ann Rheum Dis",
  "publication/year": "2012",
  "publication/doi": "10.1136/annrheumdis-2011-200968",
  "publication/tags": "- Rheumatoid Arthritis\n- Inflammatory Arthritis\n- Gene Expression\n- Biomarkers\n- Interleukin-6\n- C-Reactive Protein\n- Clinical Research\n- Statistical Analysis\n- Machine Learning\n- Predictive Modeling",
  "dataset/provenance": "The dataset used in this study was derived from a cohort of patients with rheumatoid arthritis (RA) and non-RA comparator groups. The total number of data points in the training cohort is 111, comprising 47 RA patients and 64 non-RA individuals. Additionally, an independent validation cohort of 62 patients with undifferentiated arthritis (UA) was included.\n\nThe data utilized in this study were collected as part of a broader research effort focused on understanding the molecular and clinical characteristics of rheumatoid arthritis and related conditions. The dataset includes various clinical and serological parameters, such as age, gender, symptom duration, tender and swollen joint counts, morning stiffness, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels, and the presence of anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF).\n\nThe dataset has been used to generate a list of differentially expressed genes, which were then employed to train a machine-learning model. This model aims to predict outcomes in patients with undifferentiated arthritis. The training cohort and validation cohort were used to assess the model's accuracy and reliability.\n\nThe dataset includes detailed clinical characteristics, which were analyzed using various statistical methods, including parametric and non-parametric analyses of variance, Mann–Whitney U tests, Pearson’s correlation coefficients, and multivariate analyses. These analyses were performed using SPSS version 15.0.\n\nThe dataset has not been previously published or used by the community in its entirety. However, the methods and some of the findings have been described in previous publications, and the data have been used internally to derive prediction rules and to train machine-learning models. The dataset is protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.",
  "dataset/splits": "There were two main data splits in the study: a training cohort and a validation cohort.\n\nThe training cohort consisted of 111 patient samples. These samples were from patients who had been assigned definitive diagnoses at the start of the study, which were confirmed after a median follow-up period of 28 months. This cohort was used to derive a discriminatory signature for rheumatoid arthritis (RA) versus non-RA.\n\nThe validation cohort comprised 62 samples, all from patients with undifferentiated arthritis (UA). This cohort was used to test the utility of the RA versus non-RA discriminatory signature derived from the training cohort. The characteristics of the UA cohort, such as age, acute phase response, and joint counts, fell between the measurements in the RA and control sample sets within the training cohort.\n\nFor subsequent pathway analysis, all 173 samples were pooled and then divided into four categories based on the diagnostic outcome at the end of the study. However, the specific distribution of these 173 samples across the four categories is not detailed here.",
  "dataset/redundancy": "The dataset used in this study consisted of 173 patient samples, which were split into two main cohorts: a training cohort and a validation cohort. The training cohort comprised 111 samples from patients who had received definitive diagnoses at the start of the study, with a median follow-up of 28 months. This cohort was used to derive a discriminatory 'signature' for rheumatoid arthritis (RA) versus non-RA conditions. The validation cohort consisted of 62 samples from patients with undifferentiated arthritis (UA), which were used to test the utility of the derived signature based on diagnostic outcomes over the same follow-up period.\n\nThe training and validation sets were independent. The independence was enforced by ensuring that the training cohort samples had confirmed diagnoses at the outset, while the validation cohort samples represented UA patients whose diagnostic outcomes were determined over the follow-up period. This approach helped to validate the robustness of the signature derived from the training cohort.\n\nThe characteristics of the UA cohort in terms of age, acute phase response, joint counts, and other measurements fell between those of the RA and control groups within the training cohort. This distribution is consistent with the nature of UA, which represents an early stage of arthritis where the diagnosis is not yet clear. The dataset's structure and distribution align with the need for robust machine-learning models in medical diagnostics, where independent validation is crucial for assessing the generalizability of the findings.",
  "dataset/availability": "Not enough information is available.",
  "optimization/algorithm": "The machine-learning algorithm class used in our study is Support Vector Machine (SVM). This is a well-established and widely used supervised learning method for classification and regression tasks.\n\nThe SVM algorithm employed is not new; it has been extensively used in various fields, including bioinformatics and medical research, due to its effectiveness in handling high-dimensional data and its robustness in classification tasks.\n\nThe reason the SVM algorithm was not published in a machine-learning journal is that our focus was on applying this established method to a specific medical problem—predicting the progression of undifferentiated arthritis (UA) to rheumatoid arthritis (RA), particularly in the diagnostically challenging ACPA-negative subset. The innovation lies in the application and validation of the SVM in this clinical context, rather than in the development of a new algorithm. Our work contributes to the medical field by demonstrating the utility of SVM in improving diagnostic tools for RA, rather than advancing the field of machine learning itself.",
  "optimization/meta": "The model indeed uses data from other machine-learning algorithms as input, specifically leveraging a Support Vector Machine (SVM) classification model. This SVM model was initially trained on a dataset of patients with undifferentiated arthritis (UA) to predict progression to rheumatoid arthritis (RA).\n\nThe SVM model's performance was evaluated on a validation cohort, where it demonstrated high sensitivity and specificity, particularly in the diagnostically challenging ACPA-negative UA subset. To enhance predictive accuracy further, a modified risk metric was developed. This metric combines features from the Leiden prediction rule with a 12-gene risk metric derived from gene expression profiles.\n\nThe Leiden prediction rule is an existing tool that has been used to predict the likelihood of developing RA among UA patients. By integrating this rule with the 12-gene risk metric, the model aims to improve the utility of the prediction rule for seronegative UA patients. The area under the receiver operating characteristic (ROC) curve for this combined metric was found to be 0.84, indicating a strong discriminatory utility.\n\nRegarding the independence of the training data, it is clear that the validation cohort used to test the SVM model and the combined risk metric was independent of the training cohort. The training cohort consisted of patients with definitive diagnoses at inception, while the validation cohort included UA patients whose diagnostic outcomes were followed over time. This independence ensures that the model's performance is evaluated on unseen data, providing a robust assessment of its generalizability.",
  "optimization/encoding": "The data encoding and preprocessing for the machine-learning algorithm involved several steps to ensure the quality and reliability of the input data. Initially, CD4 T-cell RNA was extracted and quality-controlled using an Agilent 2100 Bioanalyzer. The median RNA integrity number of the samples used was 9.4, indicating high-quality RNA. cRNA generated from 250 ng of total RNA was hybridized to the Illumina Whole Genome 6v3 BeadChip, which represents 48,804 known genes and expressed sequence tags.\n\nThe array data were processed using Illumina BeadStudio software, followed by normalization, batch correction, filtering, and quality control. To define differential expression, a fold-change cutoff of 1.2 between comparator groups was combined with a significance level cutoff of p<0.05, corrected for multiple testing using the false-discovery-rate method. Genes identified through this process were used to train a support vector machine (SVM) classification model based on known outcomes among a training sample set.\n\nFor the quantitative real-time PCR, CD4 T-cell total RNA samples were reverse transcribed using Superscript II reverse transcriptase and random hexamers. Real-time PCR reactions were performed using a custom-made TaqMan Low Density Array on a 7900HT real-time PCR system. The raw data were normalized and expressed relative to the housekeeping gene β-actin as 2−∆Ct values.\n\nGeneral statistical analyses included parametric and non-parametric analyses of variance, Mann–Whitney U tests, Pearson’s correlation coefficients, intra-class correlations, multivariate analyses, and the construction of receiver operator characteristic (ROC) curves. These analyses were performed using SPSS version 15.0. The data encoding and preprocessing steps ensured that the machine-learning algorithm received high-quality, normalized data suitable for accurate and reliable analysis.",
  "optimization/parameters": "In our study, we utilized a set of 12 genes as input parameters for our support vector machine (SVM) classification model. These genes were identified through differential expression analysis between patients with rheumatoid arthritis (RA) and those with non-RA diagnoses. The selection of these 12 genes was based on a fold-change cut-off of 1.2 and a significance level cut-off of p<0.05, corrected for multiple testing using the false-discovery-rate method. This approach ensured that the genes selected were robustly differentially expressed and relevant to the classification task.\n\nThe choice of 12 genes was further validated through quantitative real-time PCR (qRT-PCR) analysis, which confirmed the differential expression of six out of seven tested genes in a subset of samples. This validation step added confidence to the selection of these genes as input parameters for our model.\n\nAdditionally, we constructed a receiver operator characteristic (ROC) curve for the risk metric derived from the 12-gene signature, which showed promising discriminatory utility with an area under the curve of 0.85. This further supported the use of these 12 genes as input parameters for our classification model.",
  "optimization/features": "The study utilized a 12-gene signature as the primary input feature set for the classification model. This signature was derived from a larger dataset of differentially expressed genes identified through microarray analysis. The selection of these 12 genes was based on a significance threshold robust to multiple test correction, specifically a false-discovery-rate p-value of less than 0.05 and a fold-change greater than 1.2. This process ensured that the selected genes were both statistically significant and biologically relevant.\n\nFeature selection was indeed performed, and it was conducted using only the training cohort. This cohort consisted of 111 patient samples, which were divided into those with a confirmed diagnosis of rheumatoid arthritis (RA) and those with non-RA diagnoses. The 12-gene signature was derived from this training set alone, ensuring that the validation process was independent and unbiased. The validation cohort, comprising 62 samples from undifferentiated arthritis (UA) patients, was used to test the utility of the derived signature without any prior knowledge of the gene selection process. This approach helps to validate the generalizability and robustness of the 12-gene signature in predicting the progression to RA, particularly in the diagnostically challenging ACPA-negative UA subset.",
  "optimization/fitting": "The study involved a training cohort of 111 patients and a validation cohort of 62 patients. The number of parameters, specifically the 12-gene signature, is relatively small compared to the number of training points, which helps mitigate the risk of overfitting. To further ensure robustness, a significance threshold with multiple test correction (false-discovery-rate p<0.05) was applied, which helps in identifying genuinely differentially expressed genes.\n\nTo rule out overfitting, the model's performance was validated on an independent cohort of undifferentiated arthritis (UA) patients. The support vector machine (SVM) classification model, trained on the 12-gene signature, demonstrated good sensitivity and specificity in the validation cohort, particularly in the ACPA-negative subset. This indicates that the model generalizes well to new data, reducing the likelihood of overfitting.\n\nUnderfitting was addressed by ensuring that the model captured relevant biological signals. The 12-gene signature was derived using a stringent significance threshold, and its discriminatory utility was confirmed through receiver operator characteristic (ROC) curve analysis, which showed promising results. Additionally, the model's performance was compared with existing tools like the Leiden prediction rule, and a combined metric was developed to enhance predictive accuracy, especially in the diagnostically challenging ACPA-negative UA group. This approach ensures that the model is complex enough to capture the necessary patterns in the data without being too simplistic.",
  "optimization/regularization": "Not applicable.",
  "optimization/config": "Not enough information is available.",
  "model/interpretability": "The model developed in this study is not a blackbox but rather a transparent one, as it is based on a clear and interpretable 12-gene transcriptional signature. This signature was derived from differential gene expression analysis in peripheral blood CD4 T cells between patients with early arthritis who were later diagnosed with rheumatoid arthritis (RA) and those who were not.\n\nThe 12 genes included in the signature were selected based on a significance threshold robust to multiple test correction (false-discovery-rate p<0.05) and a fold-change greater than 1.2. These genes were shown to be differentially expressed between the two groups, and their expression profiles were used to create a risk metric for progression to RA.\n\nThe model's transparency is further illustrated by the use of supervised hierarchical cluster analysis, which demonstrated a clear tendency for patients diagnosed with RA to cluster together based on their transcription profile. Additionally, quantitative real-time PCR (qRT-PCR) was used to confirm the differential expression of six out of seven selected genes from the signature in a subset of samples.\n\nThe model's interpretability is also evident in its comparison with existing tools, such as the Leiden prediction rule. By combining the 12-gene risk metric with the Leiden prediction rule, the model's utility for predicting RA in seronegative undifferentiated arthritis (UA) patients was improved.\n\nIn summary, the model's transparency and interpretability are demonstrated through the clear selection and analysis of a 12-gene signature, the use of hierarchical clustering, and the confirmation of gene expression through qRT-PCR. These factors contribute to the model's ability to provide insights into the biological processes underlying RA and to improve the prediction of disease progression in UA patients.",
  "model/output": "The model employed in our study is a classification model. Specifically, a Support Vector Machine (SVM) was used to classify patients with undifferentiated arthritis (UA) into those who would progress to rheumatoid arthritis (RA) and those who would not. The SVM was trained on a dataset of patients with confirmed RA and non-RA diagnoses, and it was then applied to a validation cohort of UA patients. The model's performance was evaluated using metrics such as sensitivity, specificity, and the area under the ROC curve, indicating its effectiveness in predicting the progression to RA, particularly in the diagnostically challenging ACPA-negative subset. Additionally, a 12-gene risk metric was derived and used to enhance the predictive power of the model, demonstrating its utility in improving diagnostic accuracy for seronegative UA patients.",
  "model/duration": "The execution time for the model was not explicitly detailed in the provided information. However, the process involved several steps, including real-time PCR reactions, data normalization, statistical analyses, and machine-learning model training and validation. These steps were performed using specific tools and software, such as the 7900HT real-time PCR system and SPSS version 15.0. The training cohort consisted of 111 samples, and the validation cohort had 62 samples. The model's performance was evaluated using metrics like sensitivity, specificity, and the area under the ROC curve. While the exact time taken for each step is not specified, the overall process involved comprehensive data analysis and model validation, which typically requires a significant amount of computational time.",
  "model/availability": "Not enough information is available.",
  "evaluation/method": "The evaluation method involved a comprehensive approach to assess the utility of a transcriptional signature for predicting the progression to rheumatoid arthritis (RA), particularly in ACPA-negative undifferentiated arthritis (UA) patients. The study utilized a training cohort consisting of 111 patient samples with definitive diagnoses, confirmed at a median follow-up of 28 months. From this cohort, a discriminatory 'signature' was derived, consisting of 12 genes that were differentially expressed in peripheral blood CD4 T cells between patients with confirmed RA and those with non-RA diagnoses.\n\nTo evaluate the robustness of this signature, a support vector machine (SVM) classification model was trained using the dataset from the training cohort. This model was then applied to an independent validation cohort of 62 UA patients. The validation cohort's diagnostic outcomes were tracked over the same follow-up period, allowing for the assessment of the model's predictive accuracy.\n\nThe performance of the SVM model was evaluated using several metrics, including sensitivity, specificity, and likelihood ratios. The model demonstrated a sensitivity of 0.68 and a specificity of 0.70 for identifying UA patients who progressed to RA. However, when applied specifically to the ACPA-negative subset of the UA validation cohort, the model showed improved performance with a sensitivity of 0.85 and a specificity of 0.75. This indicates that the transcriptional signature is particularly effective in the diagnostically challenging group of ACPA-negative UA patients.\n\nAdditionally, hierarchical cluster analysis was performed on the ACPA-negative UA samples based on their 12-gene RA signature expression profiles. This analysis further illustrated molecular similarities within the ACPA-negative RA outcome group, supporting the validity of the transcriptional signature.\n\nThe evaluation also included the construction of a receiver operator characteristic (ROC) curve for the risk metric derived from the 12-gene signature. The area under the curve (AUC) was 0.85, suggesting promising discriminatory utility. Quantitative real-time PCR (qRT-PCR) was used to validate the differential expression of seven genes from the signature in a subset of 73 samples, confirming robust differential expression for six of the seven genes.",
  "evaluation/measure": "In the evaluation of our study, several performance metrics were reported to assess the effectiveness of our 12-gene signature and the Leiden prediction rule in diagnosing rheumatoid arthritis (RA), particularly in the challenging ACPA-negative undifferentiated arthritis (UA) subgroup.\n\nFor the Support Vector Machine (SVM) classification model applied to the ACPA-negative subset of the UA validation cohort, we reported a sensitivity of 0.85 (95% CI 0.58 to 0.96) and a specificity of 0.75 (0.59-0.86). These metrics indicate the model's ability to correctly identify patients who will progress to RA (sensitivity) and those who will not (specificity).\n\nAdditionally, we constructed receiver operator characteristic (ROC) curves to evaluate the discriminatory utility of the Leiden prediction rule and our 12-gene risk metric. The area under the ROC curve (AU ROC) for the Leiden prediction rule in the entire UA cohort was 0.86 (SEM=0.05), which is comparable to previously reported values. However, its performance diminished in the ACPA-negative sub-cohort, with an AU ROC of 0.74 (SEM=0.08). Our 12-gene risk metric showed equivalent discriminatory utility in this sub-cohort, with an AU ROC of 0.78 (SEM=0.08). By combining the Leiden prediction rule with our 12-gene risk metric, we improved the utility of the prediction rule for seronegative UA patients, achieving an AU ROC of 0.84 (SEM=0.06).\n\nThese performance metrics are representative of those commonly reported in the literature for similar diagnostic tools in rheumatology. Sensitivity, specificity, and AU ROC are standard metrics used to evaluate the performance of diagnostic tests, and our results provide a comprehensive assessment of our model's effectiveness in identifying RA in ACPA-negative UA patients.",
  "evaluation/comparison": "In the evaluation of our 12-gene signature for predicting rheumatoid arthritis (RA) in undifferentiated arthritis (UA) patients, a comparison was made with an existing prediction tool, the Leiden prediction rule. This comparison was crucial to assess the added value of our gene signature in diagnosing RA, particularly in the diagnostically challenging ACPA-negative UA subset.\n\nThe Leiden prediction rule, which has been previously validated, was applied to our UA cohort. Its performance in our cohort was comparable to that reported in earlier studies, with an area under the receiver operating characteristic (AU ROC) curve of 0.86. However, when applied exclusively to the ACPA-negative subset, the rule's performance diminished, showing an AU ROC curve of 0.74.\n\nOur 12-gene risk metric was then evaluated in the same ACPA-negative sub-cohort. It demonstrated equivalent discriminatory utility to the Leiden prediction rule, with an AU ROC curve of 0.78. To further enhance the predictive power, a modified risk metric was derived by combining all features of the Leiden prediction rule with our 12-gene risk metric. This combined approach significantly improved the utility of the prediction rule for seronegative UA patients, achieving an AU ROC of 0.84.\n\nThis comparison highlights the potential of our 12-gene signature to complement and enhance existing diagnostic tools, particularly in cases where traditional markers like ACPA are absent. The evaluation involved a direct comparison with a well-established prediction rule, providing a robust benchmark for assessing the performance of our gene signature.",
  "evaluation/confidence": "In our study, we employed various statistical methods to ensure the robustness and significance of our findings. For instance, we used non-parametric analyses of variance, such as the Kruskal-Wallis test, to compare baseline profiles across different outcome groups. Post-hoc analyses were conducted using Dunn’s multiple comparison test, with significance levels denoted by asterisks (p<0.05, 0.01, and 0.001).\n\nWe also performed parametric and non-parametric analyses of variance, Mann–Whitney U tests, Pearson’s correlation coefficients, and intra-class correlations to assess the relationships and differences between various groups. These statistical tests provided confidence intervals and p-values, allowing us to determine the statistical significance of our results.\n\nThe construction of receiver operator characteristic (ROC) curves further aided in evaluating the performance of our predictive models. These curves, along with the associated area under the curve (AUC) values, offered a visual and quantitative measure of the models' discriminatory power.\n\nIn summary, our study incorporated rigorous statistical analyses to ensure that the performance metrics were reliable and that the results were statistically significant. This approach allowed us to confidently claim the superiority of our methods over others and established baselines.",
  "evaluation/availability": "Not enough information is available."
}